slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
233,521-233,550 of 319,975
11
Includes an award badge in the top right corner.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Traction1 hit
12
The slide uses a structured layout to categorize services into Secondary Market Advisory, Tailored Capital Raise, and Primary Fundraise.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Traction1 hit
13
Includes a 'Deals of the Year 2022' badge from The Banker.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Traction1 hit
14
The central Venn diagram illustrates the intersection of Products, Sectors, and Regions as the firm's core value proposition.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations 1 hit
15
The slide uses a three-row layout to categorize ESG initiatives. The governance section includes two donut charts representing board diversity.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations 1 hit
16
The slide uses a three-column layout to categorize HR/DEI initiatives.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations 1 hit
17
The chart shows a break in the timeline between 2014 and 2020.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
18
The slide uses a table-like structure to correlate market opportunity (fee pool) with firm performance (market share) and investment (MD additions).Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations 1 hit
19
The 2023 pre-tax margin shows a negative value due to specific investments mentioned in the footnotes.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · FinancialsLoop · Maturity Curve1 hit
20
Includes Moelis branding and page number 19.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Financials1 hit
21
The chart illustrates a consistent history of capital allocation to shareholders.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Financials1 hit
22
The chart shows Moelis significantly outperforming its benchmarks and peers over the 10-year period.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations Beat · Financials1 hit
23
Moelis & Company | Investor Presentation Deck | 24 slidesMoelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations 1 hit
24
Includes footnotes explaining specific reclassifications related to MA Financial Group shares and employee compensation.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Pitch deck Investor relations 1 hit
01
NeuroSense Therapeutics | Investor Presentation Deck | 27 slidesNeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
02
NeuroSense Therapeutics | Investor Presentation Deck | 27 slidesNeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a five-column icon-based layout to present key value propositions.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a standard pharmaceutical pipeline visualization format.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
NeuroSense Therapeutics | Investor Presentation Deck | 27 slidesNeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a grid layout to showcase the board members with headshots, credentials, and associated logos.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
07
Uses a 'before and after' visual comparison of a patient's health progression over time.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem Statement1 hit
08
The slide uses a three-column layout to explain the biological mechanisms of the drug combination.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The slide shows a pharmacokinetic study in mice comparing Ciprofloxacin alone vs. combination therapy.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Includes statistical significance markers (*, ***) and source citation.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
Includes a collaboration credit with Dr. Justin Ichida at USC.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Includes box plots for baseline comparison and line charts for longitudinal treatment effects.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
Includes a flow diagram of the trial phases and a table of baseline characteristics.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide highlights safety data; the bottom text emphasizes that adverse events were transient and anticipated.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
Includes statistical significance markers and sample sizes (N) for each time point.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
16
Includes both a longitudinal line chart and a bar chart comparing total points lost at 12 months.NeuroSense Therapeutics | Investor Presentation Deck | 27 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Traction1 hit